Alterity Therapeutics Limited

Feb 09, 2021

Alterity Therapeutics announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson's disease clinical trials

Jan 07, 2021

Dr David Stamler Appointed CEO

Dec 21, 2020

Alterity and UniQuest partner to reverse bacterial resistance to antibiotics

Nov 16, 2020

Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases

Oct 26, 2020

Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study

Aug 03, 2020

New data independently confirms and extends laboratory findings and expands safety profile of ATH434

Jul 30, 2020

Alterity Releases Appendix 4C - Q4 FY20 Quarterly Cash Flow Report

May 20, 2020

Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology

Apr 30, 2020

Alterity Therapeutics Limited Releases Its Appendix 4C - Q3 FY20 Quarterly Cash Flow Report